Incyte gets another graft-versus-host disease drug approval, this time with partner Syndax
Incyte and partner Syndax Pharmaceuticals on Tuesday secured regulatory clearance to market a third-line chronic graft-versus-host disease treatment, or cGVHD.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.